ABSTRACT
INTRODUCTION
Infertility is defined as failure to achieve a successful pregnancy after 12 months or more of appropriately timed unprotected intercourse or therapeutic donor insemination 1 . It is estimated to affect 186 million people worldwide 2 . While many treatments can help infertile couples, areas of the world with the highest rates of infertility are often those with poor access to fertility treatment due to limited resources 2 .
About 25% of infertility is caused by ovulatory disorders 3 . The World Health Organization (WHO) classifies these into three groups. Group II includes women with hypothalamic-pituitary-ovarian dysfunction (predominantly polycystic ovary syndrome; PCOS) 3 . Ovulation induction is by far the most commonly used treatment for women with WHO group II anovulation and clomiphene citrate (CC) has historically been the drug most used 4 . CC is a non-steroidal triphenylethylene derivative that exhibits both estrogenic agonist and estrogenic antagonist properties. Its mechanism of action for ovulation induction is by competitive binding to estrogen receptors in the hypothalamus and pituitary reducing signaling of estrogen via its receptors. This interferes with the feedback mechanism of endogenous estrogen resulting in an increase in FSH and LH secretion to stimulate ovarian follicular production 5, 6 . If ovulation cannot be achieved with increasing doses of CC, the patient is labeled as CC resistant, while women who are not pregnant after six ovulatory cycles with CC are labeled as having CC failure 3, 7 . In many fertility guidelines, CC is recommended as the first-line treatment for women with group II anovulation or PCOS who wish to conceive 3, [8] [9] [10] [11] . However, other guidelines recommend both CC and letrozole as first-line treatments [12] [13] [14] [15] . While cost differences between letrozole and CC in highly resourced countries in Europe, NorthAmerica, Australia and New Zealand are not a concern, the threefold greater cost of letrozole over CC is important in low-resourced countries such as Egypt and India.
It is hypothesized that CC resistance and failure are related to anti-estrogenic effects of CC on the endometrium, cervical mucus and uterine blood flow [16] [17] [18] . However, such an impact of CC and other ovulation induction drugs on endometrial thickness (EMT) in women with ovulatory disorders has not been assessed systematically, thus necessitating a systematic review on this topic.
METHODS

Search
Our review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reporting systematic reviews 19 . We searched for all published clinical trials studying the impact of CC alone vs other drug regimens on mid-cycle EMT in women with WHO group II ovulatory disorders. We searched the following electronic databases: MEDLINE, EMBASE, Scopus, Web of Science, The Cochrane Central Register of Clinical Trials (CENTRAL) and the non-MEDLINE subset of PubMed from inception to December 2016 (Table S1 ). We also searched the reference lists of relevant studies. We did not apply language restrictions. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42017057458).
Selection criteria
Two reviewers (M.G. and S.H.) independently screened titles and abstracts of the identified studies and read the full articles for final inclusion. Disagreement between the reviewers was resolved through discussion with a third reviewer (B.M.). We only included randomized controlled trials (RCTs) in the review. We included RCTs reporting on mid-cycle EMT in women with WHO group II anovulation receiving ovulation induction with CC as one of the interventions. The included comparative drug regimens could be aromatase inhibitors, gonadotropins, CC plus adjunctive treatments or any other regimen.
Study quality assessments and data extraction
We used the risk of bias assessment tool in the Cochrane Handbook to assess the quality of included studies 20 . Then we used GRADEPRO software to generate a summary of findings table 21 . This table evaluated the overall quality of the body of evidence for EMT, ovulation, pregnancy and live birth rates in the main comparison of the study between CC and letrozole. We used the GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias) 21 .
We extracted data on the following domains: study design, trial setting, inclusion criteria, age, body mass index, duration of infertility, sample size, number of ovulation induction cycles, details of interventions and outcomes as means and standard deviations (SD) of mid-cycle EMT in mm and number of events, cycles and patients for ovulation, pregnancy and live birth. If data were missing, we contacted authors by email for additional information.
Outcomes
The outcomes of our review were mid-cycle EMT per cycle and per woman, ovulation rate per cycle detected by ultrasound scan or mid-luteal progesterone, clinical pregnancy rate per woman defined as ultrasonographic visualization of one or more gestational sacs (positive pregnancy test was included if it was the only type reported in the included studies) and live birth rate per woman randomized defined as delivery of a live baby after 24 weeks of gestation.
Statistical analysis
We performed meta-analyses by using a random effects model. We pooled weighted mean differences (WMD) with 95% confidence intervals (CI) for continuous variables (EMT) and risk ratios (RR) with 95% CI for binary variables (ovulation, pregnancy and live birth rates). In cases of high heterogeneity (I 2 ≥ 50%), we Records identified through database search (n = 1718)
• CENTRAL (n = 215)
Records excluded (n = 842)
Additional records identified through other sources (n = 0)
Full-text articles excluded (n = 54):
• Incomplete data (n = 13)
• Wrong population or intervention (n = 17)
• Non-RCTs (n = 24)
Records screened (n = 929)
Records after duplicates removed (n = 929)
Full-text articles assessed for eligibility (n = 87) performed sensitivity analyses by including studies with low risk of bias. For statistical analysis, we used Review Manager 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). In order to study the impact of publication bias, a funnel plot was produced if there were more than 10 trials included in a comparison.
RESULTS
Characteristics of included studies
Our electronic search revealed 1718 articles of which we selected 87 after screening of titles and abstracts. After full-text evaluation, we excluded 54 studies due to incomplete data (n = 13), wrong population or intervention (n = 17), or non-RCTs (n = 24) (Figure 1 and Tables S1 and S2 ). There were 33 RCTs comprising a total of 4349 women with WHO group II anovulation, undergoing 7210 treatment cycles. Of the 33 included studies, participants were women with PCOS (without CC resistance) in 25 studies , women with CC-resistant PCOS in five studies [47] [48] [49] [50] [51] , women with WHO group II anovulation (with or without PCOS) in two studies 52, 53 and women with WHO group II anovulation (without PCOS) in one study 54 . The characteristics of these 33 included studies are listed in Table 1 . The average quality of the studies was low. Risk of bias for included studies is presented in a summary table ( Figure S1 ).
We 30, 36 . Endometrial thickness was reported in all included RCTs. Live birth rate was reported in seven RCTs 27, 29, 34, [40] [41] [42] 54 . Pregnancy rate was reported in all EMT, OR, PR * Number of participants. CC, clomiphene citrate; CoQ10, coenzyme Q10; DEX, dexamethasone; EE, ethinyl estradiol; EMT, endometrial thickness; hMG, human menopausal gonadotropin; ISMN, isosorbide mononitrate; LBR, live birth rate; NAC, N-acetyl cysteine; NO, nitric oxide; OR, ovulation rate; PCOS, polycystic ovary syndrome; PR, pregnancy rate; rFSH, recombinant follicle stimulating hormone; uFSH, urinary follicle stimulating hormone.
RCTs except two 31, 49 ; it was reported as clinical pregnancy rate except in four studies 25, 27, 30, 36 in which it was reported as a positive pregnancy test. Ovulation rate per cycle was reported in all RCTs except for four 32, 34, 37, 45 .
Results of meta-analyses
Results of meta-analyses are summarized in Table S3 .
CC vs letrozole
Pooled analysis of five studies showed a lower live birth rate in the CC group (RR, 0.70; 95% CI, 0.49-0.98; I 2 = 35%) 27, 29, 40, 41, 54 ( Figure 2 ). Pooled analysis of 15 studies showed EMT to be lower (WMD, −1.39; 95% CI, −2.27 to −0.51; I 2 = 100%) with a lower pregnancy rate (RR, 0.78; 95% CI, 0.63-0.95; I 2 = 43%) in the CC group than in the letrozole group (Figures 2 and 3 
CC vs anastrozole
Two studies compared CC with anastrozole in different doses 52, 53 . Pooled analysis of these two studies showed no evidence of significant difference in EMT (WMD, −0.12; 95% CI, −2.17 to 1.94; I 2 = 89%) and no statistical difference in pregnancy rate (RR, 2.44; 95% CI, 0.90-6.66; I 2 = 0%) between the CC group and the 1 mg anastrozole group, with a higher ovulation rate (RR, 1.98; 95% CI, 1.43-2.76; I 2 = 0%) in the CC group than the 1 mg anastrozole group. 23 Aygen (2007) 24 Bayar (2006) 27 Chen (2016) 28 Dehbashi (2009) 29 Hendawy (2011) 51 Kar (2012) 33 Moussa (2016) 38 Nahid (2012) 39 Ray (2012) 40 Roy (2012) 41 Selim (2012) 44 Seyedoshohadaei (2012) 54 Sheikh-El-Arab Elsedeek (2011) 46 Badawy (2009) 25 Total events Total (95% CI) Heterogeneity: tau 2 = 0.06; chi 2 = 24.73, df = 14 (P = 0.04); I 2 = 43% Test for overall effect: Z = 2.44 (P = 0.01) 42 .
CC vs tamoxifen
Pooled analysis of three studies showed no statistical difference in EMT (WMD, −1.34; 95% CI, −2.70 to 0.01; I 2 = 96%) and a comparable pregnancy rate (RR, 1.36; 95% CI, 0.86-2.15; I 2 = 53%) between the groups (Figures 2 and 3 ). Pooled analysis of two studies that reported on ovulation rate showed this to be comparable between the groups (RR, 1.12; 95% CI, 0.88-1.43; I 2 = 55%; Figure 4 ) 26, 38 .
CC vs CC plus NAC
Pooled analysis of three studies showed EMT to be lower in the CC group (WMD, −1.51; 95% CI, −1.98 to −1.04; I 2 = 45%) and a lower ovulation rate (RR, 0.58; 95% CI, 0.44-0.76; I 2 = 0%; Figures 3 and 4) . Pooled analysis of the two studies showed a statistically significant lower pregnancy rate in the CC group (RR, 0.47; 95% CI, 0.25-0.89; I 2 = 0%; Figure 2 ) 35, 43 .
CC vs CC plus coenzyme Q10
One study that compared CC with CC plus coenzyme Q10 50 showed EMT to be lower in the CC group (WMD, −1.79; 95% CI, −2.16 to −1.42), and lower ovulation (RR, 0.24; 95% CI, 0.13-0.41) and pregnancy (RR, 0.16; 95% CI, 0.05-0.51) rates in the CC group.
CC vs CC plus dexamethasone
One study that compared CC with CC plus dexamethasone 47 showed EMT to be lower in the CC group (WMD, −1.79; 95% CI, −2.31 to −1.27), and lower ovulation (RR, 0.20; 95% CI, 0.09-0.43) and pregnancy (RR, 0.13; 95% CI, 0.03-0.51) rates in the CC group.
CC vs CC plus ethinyl estradiol
One study that compared CC with CC plus ethinyl estradiol 37 showed EMT to be lower in the CC group (WMD, −0.80; 95% CI, −1.56 to −0.04), with a lower clinical pregnancy rate in the CC group (RR, 0.35; 95% CI, 0.13-0.89), while there was no statistical difference in ongoing pregnancy rate between the groups (RR, 0.41; 95% CI, 0.15-1.09).
CC vs CC plus ISMN as NO donor
Pooled analysis of two studies showed EMT to be lower in the CC group than the 20 mg NO donor group (WMD, −1.75; 95% CI, −2.08 to −1.41; I 2 = 0%), with lower ovulation (RR, 0.59; 95% CI, 0.44-0.78; I 2 = 0%) and pregnancy (RR, 0.52; 95% CI, 0.29-0.96; I 2 = 0%) rates in the CC group than the 20 mg NO donor group (Figures 2-4) .
CC vs letrozole plus metformin
One study that compared CC with letrozole plus metformin 24 showed EMT to be lower in the CC group (WMD, −2.80; 95% CI, −3.39 to −2.20) but a comparable ovulation rate (RR, 0.90; 95% CI, 0.56-1.43) without statistical difference in pregnancy rate (RR, 0.50; 95% CI, 0.06-3.91) between the groups.
CC vs letrozole plus human menopausal gonadotropin
One study that compared CC with letrozole plus human menopausal gonadotropins 28 showed EMT to be lower in the CC group (WMD, −3.20; 95% CI, −3.38 to −3.01), with a comparable ovulation rate (RR, 0.93; 95% CI, 0.80-1.09) and lower pregnancy rate (RR, 0.59; 95% CI, 0.37-0.93) in the CC group.
CC vs raloxifene
One study that compared CC with raloxifene 31 showed EMT (WMD, −0.60; 95% CI, −1.81 to 0.61) not to differ between the groups without statistical difference in ovulation rate (RR, 1.49; 95% CI, 0.77-2.89) between the groups. 27 Chen (2016) 28 Dehbashi (2009) 29 Hendawy (2011) 51 Kar (2012) 33 Moussa (2016) 38 Nahid (2012) 39 Ray (2012) 40 Roy (2012) 41 Selim (2012) 44 Seyedoshohadaei (2012) 54 Sheikh-El-Arab Elsedeek (2011) 46 Badawy (2009) 27 Chen (2016) 28 Dehbashi (2009) 29 Hendawy (2011) 51 Kar (2012) 33 Moussa (2016) 38 Nahid (2012) 39 Roy (2012) 41 Selim (2012) 44 Sheikh-El-Arab Elsedeek (2011) 46 Badawy (2009) 25 Total (95% CI)
Heterogeneity: tau 2 = 0.01; chi 2 = 22.57, df = 12 (P = 0.03); I 2 = 47% Test for overall effect: Z = 0.81 (P = 0.42) 35 Sahin (2004) 
CC vs CC plus urinary follicle stimulating hormone
One study that compared CC with CC plus urinary follicle stimulating hormone 22 showed EMT to be slightly lower in the CC group (WMD, −0.20; 95% CI, −0.32 to −0.08), while ovulation (RR, 0.98; 95% CI, 0.81-1.19) and pregnancy (RR, 0.90; 95% CI, 0.46-1.78) rates did not differ.
CC vs CC plus L-carnitine
One study that compared CC with CC plus L-carnitine 48 showed EMT to be lower in the CC group (WMD, −4.58; 95% CI, −4.77 to −4.39), with lower ovulation (RR, 0.27; 95% CI, 0.17-0.44) and pregnancy (RR, 0.02; 95% CI, 0.00-0.17) rates in the CC group.
CC vs recombinant follicle stimulating hormone
One study compared CC with recombinant follicle stimulating hormone 34 and showed no evidence of significant differences in EMT (WMD, −0.08; 95% CI, −0.89 to 0.73), pregnancy (RR, 0.71; 95% CI, 0.23-2.15) and live birth (RR, 0.85; 95% CI, 0.26-2.73) rates between the groups.
CC vs phytoestrogens
One study that compared CC with phytoestrogens 32 showed EMT to be lower in the CC group (6.9 mm in the CC group vs 8.3 mm in phytoestrogens group; P < 0.0004) without statistical difference in pregnancy rate (RR, 0.49; 95% CI, 0.05-5.23) between the groups.
CC vs CC plus phytoestrogens
One study that compared CC with CC plus phytoestrogens 45 showed lower EMT (WMD, −4.40; 95% CI, −4.81 to −3.99) and lower pregnancy rate in the CC group (RR, 0.46; 95% CI, 0.34-0.62).
Sensitivity analysis
In the three studies with low risk of allocation concealment bias 27, 41, 44 , the comparison between CC and letrozole showed lower EMT in the CC group (WMD, −1.68; 95% CI, −3.27 to −0.08; I 2 = 98%). However, including studies with low risk of randomization bias 25, 27, 33, 38, 41, 44, 46, 51, 54 , performance bias 29,46,51 and detection bias 29, 44, 46 showed a similar effect estimate but without statistical significance, which could be due to low power of the studies.
In comparison between CC and tamoxifen, exclusion of one study 38 showed a lower EMT in the CC group (WMD, −0.72; 95% CI, −1.07 to −0.36; I 2 = 35%) with a higher pregnancy rate in the CC group (RR, 1.56; 95% CI, 1.08-2.24; I 2 = 0%; Figure S2 ).
In the comparison between CC and letrozole, exclusion of one study with participants with PCOS resistant to CC did not affect the effect estimate for all outcomes 51 . In the comparison between CC and CC plus NAC, exclusion of one study with participants with PCOS resistant to CC did not affect the effect estimate for all outcomes 49 . Also, we performed an additional analysis in which we included one additional large RCT 55 . This study did not report on mid-cycle EMT, but reported on ovulation, pregnancy and live birth in the main comparison between CC and letrozole. This additional analysis showed no change from our initial results ( Figure S3 ).
Publication bias
Funnel plots were produced for EMT, ovulation and pregnancy rates in comparison between CC and letrozole. For ovulation and pregnancy outcomes there was strong asymmetry suggesting high risk of publication bias. The EMT funnel plot was almost symmetrical ( Figure S4 ). There were not enough studies for other comparisons.
Quality of the evidence
The quality of the evidence was rated as very low for all outcomes in our main comparison between CC and letrozole ( Table 2 ). The findings showed that in a population in which 67%, 33% and 32% achieve ovulation, pregnancy and live birth, respectively, using letrozole, about 60-70%, 21-31% and 16-32% would achieve ovulation, pregnancy and live birth, respectively, using CC. Also, EMT was 1.4 mm lower in the CC group compared with the letrozole group.
DISCUSSION
Summary of key findings
Our systematic review and meta-analysis on the effect of CC and other ovulation induction drugs in infertile women with WHO group II anovulation showed that CC resulted in lower endometrial thickness and lower pregnancy and live birth rates than letrozole for comparable ovulation rates. When compared with NO donor or NAC, CC resulted in lower endometrial thickness and lower ovulation and pregnancy rates, but the number of studies on these comparisons was limited. We found no evidence of statistically significant differences in EMT, ovulation and pregnancy rates when comparing CC with tamoxifen, raloxifene, recombinant follicle stimulating hormone and phytoestrogens.
Quality of evidence
The overall quality of evidence in the main comparison between CC and letrozole was rated as very low. Possible reasons include unclear or high risk of selection, detection and performance bias in most of the included studies and substantial heterogeneity that was not improved by sensitivity analyses. Furthermore, there was a high possibility of publication bias demonstrated by strong asymmetry in the funnel plots. 
Very low †** GRADE Working Group grades of evidence -high quality: we are very confident that the true effect lies close to that of the estimate of the effect; moderate quality: we are moderately confident in the effect estimate i.e. the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low quality: our confidence in the effect estimate is limited i.e. the true effect may be substantially different from the estimate of the effect; very low quality: we have very little confidence in the effect estimate i.e. the true effect is likely to be substantially different from the estimate of the effect. *Risk in intervention group (and its 95% CI) is based on assumed risk in comparison group and relative effect of intervention (and its 95% CI). †Most studies have unclear or high risk of selection, detection and performance bias. ‡There is substantial heterogeneity that was not improved in sensitivity analyses. §Funnel plot for this outcome is almost symmetrical. ¶Funnel plot for this outcome has strong asymmetry. **Downgraded one level for imprecision (total events < 300). EMT, endometrial thickness; RCTs, randomized controlled trials; RR, risk ratio.
Strengths and limitations
Our study dealt with a topic that has not been addressed thoroughly in systematic reviews. We focused our analysis on CC, as this is, in many guidelines, still the most commonly recommended drug as first-line treatment for ovulation induction 3, [8] [9] [10] [11] . Another strength of our systematic review was that we did not use language restrictions and included trials published as abstracts in order to reduce publication bias as much as possible. However, there were also limitations. The average quality of the included studies was low. Most studies were underpowered and the data on EMT in comparison of CC with letrozole, CC plus metformin and tamoxifen indicated considerable heterogeneity, which was not reduced after sensitivity analysis. Potential explanations for such heterogeneity are different drug protocols (dosage, duration and treatment days), publishing dates (from 2006 onwards), improvements in ultrasound equipment and measurement technique, and discrepancies in EMT values between groups and between studies. We reported EMT both per cycle and per woman, although women, not cycles, were the unit of randomization. Data for EMT per woman were available in only eight studies with one treatment cycle. The other studies reported EMT measurements in multiple treatment cycles. Despite this heterogeneity, we found an overall lower EMT in the CC group. Another limitation was that our search strategy was based on the primary outcome mid-cycle EMT, so estimates of ovulation, pregnancy and live birth were not based on all the available evidence.
Comparison with previous reviews
Most of the systematic reviews comparing ovulation induction drugs in women with WHO group II ovulatory disorders have not reported on EMT 4, 7, [56] [57] [58] [59] [60] [61] [62] . Ding et al. 63 compared CC used in the luteal phase vs CC used in the follicular phase and found significantly thicker EMT in the latter group after pooled analysis of four studies.
Another meta-analysis reported mid-cycle EMT in five studies but pooled analysis was not performed due to the significant heterogeneity 64 . Regarding ovulation and pregnancy rates, results of recent studies showed that letrozole led to higher ovulation and pregnancy rates in women with PCOS 59, [65] [66] [67] . Our study is partially in agreement with these studies; it showed greater mid-cycle EMT, comparable ovulation, and higher pregnancy and live birth rates in the letrozole group.
On the other hand, Misso et al. 7 found comparable ovulation rates between CC and letrozole (RR, 0.94; 95% CI, 0.82-1.07; I 2 = 0%) while the pregnancy rate was higher in the letrozole group, albeit there was no evidence of significant difference (RR, 1.53; 95% CI, 0.91-2.58; I 2 = 50%). Brown et al. 6 found no evidence of a difference between CC and tamoxifen in ovulation and pregnancy rates while finding higher rates of both when adding dexamethasone to CC compared with CC alone, and these results are also in agreement with our study results. In women with unexplained subfertility undergoing intrauterine insemination, a recent meta-analysis reported no difference in EMT between CC and letrozole (WMD, −0.84; 95% CI, −1.97 to 0.28) 68 . A large RCT showed no statistical difference in pregnancy (absolute difference, 5.9%; 95% CI, −1.0 to 12.9%) and live birth rates (absolute difference, 4.6%; 95% CI, −1.9 to 11.1%) between CC and letrozole groups 69 . This raises the question of the mechanisms by which letrozole led to better results than CC in women with PCOS and not those with unexplained infertility.
Implications
We found that anovulatory women with a thin endometrium using CC had lower pregnancy and live birth rates compared with letrozole despite ovulation. While in highly resourced settings CC can be easily replaced by letrozole, in low-resourced settings its low price still makes CC the treatment of first choice. Also, CC is a registered drug for ovulation induction, while letrozole is not. Furthermore, the issue of risk of congenital anomalies following CC or letrozole is still a concern. A large retrospective study on 626 babies reported anomalies in 3.9%, 2.5% and 2.9% following women pregnant after CC, letrozole or natural conception, respectively 70 . It reported also higher cardiac and hypospadias anomalies following CC. Previous studies reported similar results 71, 72 . We hypothesize that thin endometrium might have contributed to lower chances of pregnancy and live birth. However, we have very little confidence in the effect estimate since numbers were small in underpowered studies and the quality of evidence was very low. These findings have to be investigated in future studies, as it could result in the choice of cheaper alternatives to letrozole, thus facilitating treatment of women in low resourced settings.
Conclusion
In women with WHO group II ovulatory disorders, ovulation induction with CC might result in lower EMT than other ovulation induction regimens. Whether the lower EMT caused the lower pregnancy and live birth rates remains to be elucidated. Letrozole seems to be beneficial for these women. However, our findings should be interpreted with caution as the quality of evidence was very low.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: This article has been selected for Journal Club.
A slide presentation, prepared by Dr Joel Naftalin, one of UOG's Editors for Trainees, is available online.
Chinese translation by Dr Yang Fang. Spanish translation by Dr Ruben Dario Fernandez.
